Einleitung

In 2018, two adverse analytical findings (AAFs) were reported concerning the specified stimulant heptaminol in the context of routine doping controls by a World Anti‐Doping Agency (WADA)‐accredited laboratory. In the course of inquests into these cases, both affected athletes declared the use of nutritional supplements, advertised as fat‐burner and pre‐workout products. These supplements did not list heptaminol as an ingredient on the respective product labels, and chromatographic‐mass spectrometric analyses confirmed the absence of heptaminol. However, both supplements declared the ingredient 2‐aminoisoheptane, a frequently observed (whilst incorrect) synonym for octodrine. Further analyses confirmed the presence of octodrine in both products. In one of the products the roughly estimated concentration of octodrine was ca. 30 mg/g. The manufacturer‐recommended dose of this supplement was one scoop (6 g) dissolved in 250 mL of water 30 min before training, corresponding to an octodrine consumption of 180 mg.